Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 26, Number 9—September 2020
Dispatch

Persistence of Severe Acute Respiratory Syndrome Coronavirus 2 in Aerosol Suspensions

Alyssa C. Fears, William B. Klimstra, Paul Duprex, Amy Hartman, Scott C. Weaver, Kenneth S. Plante, Divya Mirchandani, Jessica Ann Plante, Patricia V. Aguilar, Diana Fernández, Aysegul Nalca, Aysegul Totura, David Dyer, Brian Kearney, Matthew Lackemeyer, J. Kyle Bohannon, Reed Johnson, Robert F. Garry, Doug S. Reed1, and Chad J. Roy1Comments to Author 
Author affiliations: Tulane University School of Medicine, New Orleans, Louisiana, USA (A.C. Fears, R.F. Garry, C.J. Roy):; University of Pittsburgh, Pittsburgh, Pennsylvania, USA (W.B. Klimstra, P. Duprex, A. Hartman, D.S. Reed); University of Texas Medical Branch, Galveston, Texas, USA (S.C. Weaver, K.S. Plante, D. Mirchandani, J.A. Plante, P.V. Aguilar, D. Fernández); U.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland, USA (A. Nalca, A. Totura, D. Dyer, B. Kearney); National Institute of Allergy and Infectious Diseases, National Institutes of Health, Fort Detrick, Maryland, USA (M. Lackemeyer, J.K. Bohannon, R. Johnson)

Main Article

Figure 1

Aerosol efficiency of MERS-CoV, SARS-CoV and SARS-CoV-2 at different sites. Graph shows the spray factor (i.e., ratio of nebulizer concentration to aerosol concentration) for MERS-CoV (red), SARS-CoV (blue), and SARS-CoV2 (green). Aerosols were performed at 4 sites and with different nebulizers. AS, Aerogen Solo nebulizer; C3, Collison 3-jet nebulizer; C6, Collison 6-jet nebulizer; MERS-Cov, Middle East respiratory syndrome coronavirus; S1, Tulane University, New Orleans, LA, USA; S2, National I

Figure 1. Aerosol efficiency of MERS-CoV, SARS-CoV and SARS-CoV-2 at different sites. Graph shows the spray factor (i.e., ratio of nebulizer concentration to aerosol concentration) for MERS-CoV (red), SARS-CoV (blue), and SARS-CoV2 (green). Aerosols were performed at 4 sites and with different nebulizers. AS, Aerogen Solo nebulizer; C3, Collison 3-jet nebulizer; C6, Collison 6-jet nebulizer; MERS-Cov, Middle East respiratory syndrome coronavirus; S1, Tulane University, New Orleans, LA, USA; S2, National Institutes of Health Integrated Research Facility, Fort Detrick, MD, USA; S3, US Army Medical Institute for Infectious Diseases, Fort Detrick, MD, USA; S4, University of Pittsburgh, Pittsburgh, PA, USA; SARS-CoV, severe acute respiratory syndrome coronavirus; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

Main Article

1These authors contributed equally to this article.

Page created: June 15, 2020
Page updated: August 19, 2020
Page reviewed: August 19, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external